Colinz Labs

{
  "main_header": {
    "sid": 621096,
    "name": "Colinz Labs",
    "stock_name": "Colinz Labs",
    "full_name": "Colinz Laboratories Ltd",
    "name_url": "stocks-analysis/colinz-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "71.26",
    "chg": -3.74,
    "chgp": "-4.99%",
    "dir": -1,
    "prev_price": "75.00",
    "mcapval": "19.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531210,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE923C01011",
    "curr_date": "Sep 18, 03:30 PM",
    "curr_time": "19:49 PM",
    "last_traded_at": "Sep 18, 03:30 PM IST",
    "bse_nse_vol": "1.92 k",
    "exc_status": "Active",
    "traded_date": "Sep 18, 2026",
    "traded_date_str": "2026 09 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/colinz-labs-621096-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4180197",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/ColinzLaborator_valuationdot_4180197.png",
        "date": "2026-09-03 08:00:55",
        "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market sentiment amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside a broader assessment of its financial health and peer comparisons."
      },
      {
        "title": "Are Colinz Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-colinz-laboratories-ltd-latest-results-good-or-bad-4130604",
        "imagepath": "",
        "date": "2026-07-31 19:18:37",
        "description": "Colinz Laboratories Ltd's latest financial results for Q1 FY27 present a complex picture of its operational performance. The company reported a net profit of ₹2.40 crores, reflecting a significant surge compared to the previous quarter. However, this profit increase appears to be driven by extraordinary items rather than core operational strength, as indicated by the sharp decline in revenue, which fell to ₹1.24 crores—a 29.14% decrease from ₹1.75 crores in Q4 FY26.\n\nThe profit before tax margin of 233.87% raises questions about sustainability, given the low revenue figures. The operating profit, excluding other income, was just ₹0.06 crores, marking a decline in operational efficiency with an operating margin of 4.84%, down from 5.14% in the prior quarter. This suggests that while the net profit figure is striking, it does not reflect a robust operational performance.\n\nAdditionally, the company's return on..."
      },
      {
        "title": "Colinz Laboratories Q1 FY27: Exceptional Profit Surge Masks Operational Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/colinz-laboratories-q1-fy27-exceptional-profit-surge-masks-operational-concerns-4130306",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ColinzLaborator_quaterlyResult_4130306.png",
        "date": "2026-07-31 09:49:07",
        "description": "Colinz Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹20.00 crores, reported a dramatic surge in net profit for Q1 FY27, posting ₹2.40 crores compared to ₹0.17 crores in Q4 FY26—a staggering 1,311.76% quarter-on-quarter jump. However, this exceptional bottom-line performance came against a backdrop of declining revenues and deteriorating operational metrics, raising questions about the sustainability of this profit surge. The stock responded positively, gaining 2.50% on July 31, 2026, to close at ₹82.00, though the company's operational challenges remain firmly in focus."
      },
      {
        "title": "When is the next results date for Colinz Laboratories Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-colinz-laboratories-ltd-4114142",
        "imagepath": "",
        "date": "2026-07-21 23:16:49",
        "description": "The next results date for Colinz Laboratories Ltd is scheduled for 30 July 2026...."
      },
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts Signal Caution Amid Strong Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-caution-amid-strong-returns-4102920",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ColinzLaborator_valuationdot_4102920.png",
        "date": "2026-07-15 08:00:42",
        "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, moving from fair to expensive territory. This change, coupled with a recent downgrade in its Mojo Grade from Hold to Sell, raises important questions about the stock’s price attractiveness amid a backdrop of strong returns relative to the Sensex."
      },
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4092684",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/ColinzLaborator_valuationdot_4092684.png",
        "date": "2026-07-08 08:00:37",
        "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with its robust multi-year returns outperforming the Sensex, invites a closer examination of its price attractiveness relative to historical levels and peer benchmarks."
      },
      {
        "title": "Colinz Laboratories Ltd Valuation Shifts Signal Price Attractiveness Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-price-attractiveness-challenges-4076276",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ColinzLaborator_valuationdot_4076276.png",
        "date": "2026-06-29 08:00:45",
        "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, prompting a downgrade in its investment grade from Hold to Sell. With its price-to-earnings (P/E) ratio rising to 37.32 and price-to-book value (P/BV) at 1.93, the stock now trades in the 'expensive' category, raising questions about its price attractiveness relative to historical and peer benchmarks."
      },
      {
        "title": "Colinz Laboratories Surges 21.50% Amid Valuation Shift and Mixed Fundamentals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-surges-2150-amid-valuation-shift-and-mixed-fundamentals-4075486",
        "imagepath": "",
        "date": "2026-06-27 16:05:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>22 Jun:</strong> Downgrade to Sell announced amid valuation and financial concerns</p>\n                    <p><strong>22 Jun:</strong> Valuation grade shifts from attractive to fair despite strong returns</p>\n                    <p><strong>25 Jun:</strong> Stock closes at Rs.75.55, marking a 21.50% weekly gain</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.62.18</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.75.55</div><div class=\"stat-change positive\">+21.50%</div></div>\n       ..."
      },
      {
        "title": "Colinz Laboratories Ltd Downgraded to Sell Amid Valuation and Financial Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-ltd-downgraded-to-sell-amid-valuation-and-financial-concerns-4066699",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ColinzLaborator_mojoScore_4066699.png",
        "date": "2026-06-22 08:03:21",
        "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 19 June 2026. The downgrade reflects a reassessment across four critical parameters: quality, valuation, financial trend, and technicals, with valuation concerns and flat recent financial performance driving the change despite the stock’s strong market-beating returns over the past year."
      }
    ],
    "total": 624,
    "sid": "621096",
    "stock_news_url": "https://www.marketsmojo.com/news/colinz-laboratories-621096"
  },
  "announcements": [
    {
      "caption": "Post Offer Advertisement",
      "datetime": "04-Sep-2026",
      "details": "Saffron Capital Advisors Pvt Ltd (\"Manager to the Open Offer\") has submitted to BSE a copy of Post Offer Advertisement under Regulation 18(12) of The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended for the attention of the Public Shareholders of Colinz Laboratories Ltd (\"Target Company\").",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "27-Aug-2026",
      "details": "Dear Sir",
      "source": "BSE"
    },
    {
      "caption": "Reg. 34 (1) Annual Report.",
      "datetime": "20-Aug-2026",
      "details": "Dear Sir",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-09-03 08:00:55

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market sentiment amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside a broader assessment of its financial health and peer comparisons.

Read full news article

Are Colinz Laboratories Ltd latest results good or bad?

2026-07-31 19:18:37

Colinz Laboratories Ltd's latest financial results for Q1 FY27 present a complex picture of its operational performance. The company reported a net profit of ₹2.40 crores, reflecting a significant surge compared to the previous quarter. However, this profit increase appears to be driven by extraordinary items rather than core operational strength, as indicated by the sharp decline in revenue, which fell to ₹1.24 crores—a 29.14% decrease from ₹1.75 crores in Q4 FY26. The profit before tax margin of 233.87% raises questions about sustainability, given the low revenue figures. The operating profit, excluding other income, was just ₹0.06 crores, marking a decline in operational efficiency with an operating margin of 4.84%, down from 5.14% in the prior quarter. This suggests that while the net profit figure is striking, it does not reflect a robust operational performance. Additionally, the company's return on...

Read full news article

Colinz Laboratories Q1 FY27: Exceptional Profit Surge Masks Operational Concerns

2026-07-31 09:49:07

Colinz Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹20.00 crores, reported a dramatic surge in net profit for Q1 FY27, posting ₹2.40 crores compared to ₹0.17 crores in Q4 FY26—a staggering 1,311.76% quarter-on-quarter jump. However, this exceptional bottom-line performance came against a backdrop of declining revenues and deteriorating operational metrics, raising questions about the sustainability of this profit surge. The stock responded positively, gaining 2.50% on July 31, 2026, to close at ₹82.00, though the company's operational challenges remain firmly in focus.

Read full news article

When is the next results date for Colinz Laboratories Ltd?

2026-07-21 23:16:49

The next results date for Colinz Laboratories Ltd is scheduled for 30 July 2026....

Read full news article

Colinz Laboratories Ltd Valuation Shifts Signal Caution Amid Strong Returns

2026-07-15 08:00:42

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, moving from fair to expensive territory. This change, coupled with a recent downgrade in its Mojo Grade from Hold to Sell, raises important questions about the stock’s price attractiveness amid a backdrop of strong returns relative to the Sensex.

Read full news article

Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-07-08 08:00:37

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with its robust multi-year returns outperforming the Sensex, invites a closer examination of its price attractiveness relative to historical levels and peer benchmarks.

Read full news article

Colinz Laboratories Ltd Valuation Shifts Signal Price Attractiveness Challenges

2026-06-29 08:00:45

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, prompting a downgrade in its investment grade from Hold to Sell. With its price-to-earnings (P/E) ratio rising to 37.32 and price-to-book value (P/BV) at 1.93, the stock now trades in the 'expensive' category, raising questions about its price attractiveness relative to historical and peer benchmarks.

Read full news article

Colinz Laboratories Surges 21.50% Amid Valuation Shift and Mixed Fundamentals

2026-06-27 16:05:41

Key Events This Week

22 Jun: Downgrade to Sell announced amid valuation and financial concerns

22 Jun: Valuation grade shifts from attractive to fair despite strong returns

25 Jun: Stock closes at Rs.75.55, marking a 21.50% weekly gain

Week Open

Rs.62.18

Week Close

Rs.75.55

+21.50%

...

Read full news article

Colinz Laboratories Ltd Downgraded to Sell Amid Valuation and Financial Concerns

2026-06-22 08:03:21

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 19 June 2026. The downgrade reflects a reassessment across four critical parameters: quality, valuation, financial trend, and technicals, with valuation concerns and flat recent financial performance driving the change despite the stock’s strong market-beating returns over the past year.

Read full news article

View All News